Page 67 - 84_02
P. 67
Investig Drugs 2006; 7: 574–80. Paula Morales, Pilar Goya, Nadine Jagerovic
53 Gorrini C, Harris IS, Mak TW. Modulation of Angiogenesis by Targeting Vascular Endothelial
oxidative stress as an anticancer strategy. Nat Rev Cells. Mol Pharmacol 2006; 70: 51–9.
Drug Discov 2013; 12: 931–47.
68 Kogan NM, Schlesinger M, Peters M, Marincheva G,
54 Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an Beeri R, Mechoulam R. A cannabinoid anticancer
update on anticancer molecular action, toxicity and quinone, HU-331, is more potent and less cardiotoxic
novel drug delivery systems. J Pharm Pharmacol than doxorubicin: a comparative in vivo study. J
2013; 65: 157–70. Pharmacol Exp Ther 2007; 322: 646–53.
55 Dunn CJ, Goa KL. Mitoxantrone: a review of its 69 Siegel RL, Miller KD, Jemal A. Cancer statistics,
pharmacological properties and use in acute 2015. CA Cancer J Clin 2015; 65: 5–29.
nonlymphoblastic leukaemia. Drugs Aging 1996; 9:
122–47. 70 Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol
JA. Subtyping of triple-negative breast cancer:
56 Siegel D, Gibson NW, Preusch PC, Ross D. Implications for therapy. Cancer 2014; : 1–9.
Metabolism of mitomycin C by DT-diaphorase: role
in mitomycin C-induced DNA damage and 71 Hoeferlin LA, E.Chalfant CE, Park MA. Challenges in
cytotoxicity in human colon carcinoma cells. Cancer the Treatment of Triple Negative and HER2-
Res 1990; 50: 7483–9. Overexpressing Breast Cancer. J Surg Sci 2014; 1: 3–
7.
57 Cummings J, Spanswick VJ, Tomasz M, Smyth JF.
Enzymology of mitomycin C metabolic activation in 72 Foulkes WD, Smith IE, Reis-Filho JS. Triple-
tumour tissue: implications for enzyme-directed Negative Breast Cancer. N Engl J Med 2010; 363:
bioreductive drug development. Biochem Pharmacol 1938–48.
1998; 56: 405–14.
73 Hudis CA, Gianni L. Triple-negative breast cancer: an
58 Anighoro A, Bajorath J, Rastelli G. unmet medical need. Oncologist 2011; 16: 1–11.
Polypharmacology: Challenges and Opportunities in
Drug Discovery. J Med Chem 2014; 57: 7874–87. 74 Wahba HA, El-hadaad HA. Current approaches in
treatment of triple-negative breast cancer Treatment
59 M. O’Boyle N, J. Meegan M. Designed Multiple modalities of TNBC. Cancer Biol Med 2015; 1: 106–
Ligands for Cancer Therapy. Curr Med Chem 2011; 16.
18: 4722–37.
75 Caffarel MM, Andradas C, Mira E, et al.
60 Gediya LK, Njar VC. Promise and challenges in drug Cannabinoids reduce ErbB2-driven breast cancer
discovery and development of hybrid anticancer progression through Akt inhibition. Mol Cancer 2010;
drugs. Expert Opin Drug Discov 2009; 4: 1099–111. 9: 196–206.
61 Jagerovic N, Morales P, Goya P, et al. 76 Perez-Gomez E, Andradas C, Blasco-Benito S, et al.
Chromenopyrazolediones as cannabinoid quinone Role of Cannabinoid Receptor CB2 in HER2 Pro-
derivatives having anti-tumour activity. Patent oncogenic Signaling in Breast Cancer. JNCI J Natl
WO2014013117. 2014 Jan. Cancer Inst 2015; 107: djv077.
62 Jagerovic N, Morales P, Goya P, et al. Nuevas 77 Ford LA, Roelofs AJ, Anavi-Goffer S, et al. A role for
cromenoquinonas moduladoras de receptores L-alpha-lysophosphatidylinositol and GPR55 in the
cannabinoides CB2 con actividad antitumoral. Patent modulation of migration, orientation and polarization
WO2015140377. 2014 Mar. of human breast cancer cells. Br J Pharmacol 2010;
160: 762–71.
63 Morales P, Vara D, Goméz-Cañas M, et al. Synthetic
cannabinoid quinones: Preparation, in vitro 78 Shrivastava A, Kuzontkoski PM, Groopman JE,
antiproliferative effects and in vivo prostate antitumor Prasad A. Cannabidiol induces programmed cell death
activity. Eur J Med Chem 2013; 70: 111–19. in breast cancer cells by coordinating the cross-talk
between apoptosis and autophagy. Mol Cancer Ther
64 Morales P, Blasco-Benito S, Andradas C, et al. A 2011; 10: 1161–72.
selective, non-toxic CB2 cannabinoid o-quinone with
in vivo activity against triple negative breast cancer. J 79 Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán
Med Chem 2015; 58: 2256–64. M, Sánchez C. Cannabinoids: a new hope for breast
cancer therapy? Cancer Treat Rev 2012; 38: 911–28.
65 Wu A, Duan Y, Xu D, Penning TM, Harvey RG.
Regiospecific oxidation of polycyclic aromatic 80 Gomella LG, Liu XS, Trabulsi EJ, et al. Screening for
phenols to quinones by hypervalent iodine reagents. prostate cancer: the current evidence and guidelines
Tetrahedron 2010; 66: 2111–18. controversy. Can J Urol 2011; 18: 5875–83.
66 Kogan NM, Rabinowitz R, Levi P, et al. Synthesis 81 Djulbegovic M, Beyth RJ, Neuberger MM, et al.
and Antitumor Activity of Quinonoid Derivatives of Screening for prostate cancer: systematic review and
Cannabinoids. J Med Chem 2004; 47: 3800–06. meta-analysis of randomised controlled trials. BMJ
2010; 341: c4543.
67 Kogan NM, Bl C, Alvarez L, Gallily R, Schlesinger
M, Guzman M et al. A Cannabinoid Quinone Inhibits 82 Fu W, Madan E, Yee M, Zhang H. Progress of
molecular targeted therapies for prostate cancers.
182 Biochim Biophys Acta 2012; 1825: 140–52.
@Real Academia Nacional de Farmacia. Spain
